Establishment Labs Holdings announced that the first patients in the United States have successfully undergone breast augmentation with Motiva mplants. “With the FDA approval last week, we are experiencing high demand for Motiva Implants – both from surgeons and patients,” said Juan Jose Chacon-Quiros, Founder and Chief Executive Officer of Establishment Labs. “The FDA approval came as we were attending the annual conference of the American Society of Plastic Surgeons. The response was overwhelming, and our team has already talked to more than 400 plastic surgeons post announcement. Since approval, we have already doubled our team to 25 sales reps across the United States, and our story of real innovation, backed by science and data, is resonating strongly. Everything we are seeing suggests that we can be the implant of choice in the United States.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESTA:
- Establishment Labs price target raised to $50 from $45 at Citi
- Costco reports Q4 earnings beat, Cassava to settle SEC charges: Morning Buzz
- Morning Movers: Bristol Myers jumps after FDA approves schizophrenia treatment
- Closing Bell Movers: Costco slips 1% as Q4 revenue misses estimates
- Establishment Labs receives FDA approval for Motiva SmoothSilk breast impants